Cognex Corporation (NASDAQ: CGNX) today reported financial results for the first quarter of 2022. Table 1 below shows selected financial data for Q1-22 compared with Q1-21 and Q4-21.
Table 1 | ||||
(Dollars in thousands, except per share amounts) | ||||
| Revenue | Net Income | Net Income | Non-GAAP |
Quarterly Comparisons |
|
|
|
|
Current quarter: Q1-22 | $282,407 | $67,333 | $0.38 | $0.42 |
Prior year’s quarter: Q1-21 | $239,027 | $69,848 | $0.39 | $0.36 |
Change: Q1-21 to Q1-22 | 18% | (4)% | (3)% | 17% |
Prior quarter: Q4-21 | $244,065 | $53,535 | $0.30 | $0.30 |
Change: Q4-21 to Q1-22 | 16% | 26% | 27% | 40% |
*Non-GAAP net income per diluted share excludes discrete tax adjustments. A reconciliation from GAAP to Non-GAAP is shown in Exhibit 2 of this news release. |
“Overall, I am pleased with our first quarter results,” said Robert J. Willett, Chief Executive Officer of Cognex. “Revenue was the second highest of any quarter in our company’s 41-year history and operating margin was above our 30% long-term target. This solid start to the year was driven by the increasing adoption of machine vision technology and the hard work of Cognoids through difficult conditions around the world to support our customers, manage our supply chain, and continue our product development efforts.”
Mr. Willett continued, “While our Q1 results were good, we believe growth momentum is slowing. We are currently hearing from customers that automation projects are taking longer to deploy, and some are being delayed, because of supply chain challenges and staffing shortages.”
Details of the Quarter
Statement of Operations Highlights – First Quarter of 2022
Balance Sheet Highlights – April 3, 2022
Financial Outlook – Q2 2022
Non-GAAP Financial Measures
Analyst Conference Call and Simultaneous Webcast
About Cognex Corporation
Cognex Corporation designs, develops, manufactures, and markets a wide range of image-based products, all of which use artificial intelligence (AI) techniques that give them the human-like ability to make decisions on what they see. Cognex products include machine vision systems, machine vision sensors, and barcode readers that are used in factories and distribution centers around the world where they eliminate production and shipping errors.
Cognex is the world's leader in the machine vision industry, having shipped more than 3 million image-based products, representing over $9 billion in cumulative revenue, since the company's founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.
Certain statements made in this news release, which do not relate solely to historical matters, are forward-looking statements. These statements can be identified by use of the words “expects,” “anticipates,” “estimates,” “believes,” “projects,” “intends,” “plans,” “will,” “may,” “shall,” “could,” “should,” and similar words and other statements of a similar sense. These statements are based on our current estimates and expectations as to prospective events and circumstances, which may or may not be in our control and as to which there can be no firm assurances given. These forward-looking statements, which include statements regarding business and market trends, future financial performance and financial targets, the expected impact of the COVID-19 pandemic on our assets, business and results of operations, customer demand and order rates and timing of related revenue, managing supply shortages, delivery lead times, future product mix, research and development activities, sales and marketing activities, new product offerings and product development activities, capital expenditures, investments, liquidity, dividends and stock repurchases, strategic and growth plans, and estimated tax benefits and expenses and other tax matters, involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include: (1) the reliance on key suppliers to manufacture and deliver quality products; (2) the inability to obtain components for our products; (3) the failure to effectively manage product transitions or accurately forecast customer demand; (4) the inability to manage disruptions to our distribution centers; (5) the inability to design and manufacture high-quality products; (6) the impact, duration, and severity of the COVID-19 pandemic, including the availability and effectiveness of vaccines; (7) the loss of, or curtailment of purchases by, large customers in the logistics industry; (8) information security breaches; (9) the inability to protect our proprietary technology and intellectual property; (10) the inability to attract and retain skilled employees and maintain our unique corporate culture; (11) the technological obsolescence of current products and the inability to develop new products; (12) the failure to properly manage the distribution of products and services; (13) the impact of competitive pressures; (14) the challenges in integrating and achieving expected results from acquired businesses; (15) potential disruptions in our business systems; (16) potential impairment charges with respect to our investments or acquired intangible assets; (17) exposure to additional tax liabilities; (18) fluctuations in foreign currency exchange rates and the use of derivative instruments; (19) unfavorable global economic conditions, including high inflation rates; (20) business disruptions from natural or man-made disasters or public health issues; (21) economic, political, and other risks associated with international sales and operations, including the impact of the war in Ukraine; and (22) our involvement in time-consuming and costly litigation; and the other risks detailed in Cognex reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2021 and Form 10-Q for the fiscal quarter ended April 3, 2022. You should not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Cognex disclaims any obligation to update forward-looking statements after the date of such statements.
Exhibit 1 | |||||||||||
COGNEX CORPORATION | |||||||||||
Statements of Operations | |||||||||||
(Unaudited) | |||||||||||
Dollars in thousands, except per share amounts | |||||||||||
| Three-months Ended | ||||||||||
| Apr. 3, 2022 |
| Dec. 31, 2021 |
| Apr. 4, 2021 | ||||||
|
|
|
|
|
| ||||||
Revenue | $ | 282,407 |
|
| $ | 244,065 |
|
| $ | 239,027 |
|
Cost of revenue (1) |
| 78,790 |
|
|
| 69,082 |
|
|
| 54,045 |
|
Gross margin |
| 203,617 |
|
|
| 174,983 |
|
|
| 184,982 |
|
Percentage of revenue |
| 72 | % |
|
| 72 | % |
|
| 77 | % |
Research, development, and engineering expenses (1) |
| 36,054 |
|
|
| 35,489 |
|
|
| 34,105 |
|
Percentage of revenue |
| 13 | % |
|
| 15 | % |
|
| 14 | % |
Selling, general, and administrative expenses (1) |
| 80,835 |
|
|
| 82,974 |
|
|
| 72,424 |
|
Percentage of revenue |
| 29 | % |
|
| 34 | % |
|
| 30 | % |
Operating income |
| 86,728 |
|
|
| 56,520 |
|
|
| 78,453 |
|
Percentage of revenue |
| 31 | % |
|
| 23 | % |
|
| 33 | % |
Foreign currency gain (loss) |
| (444 | ) |
|
| (37 | ) |
|
| (1,008 | ) |
Investment and other income |
| 1,420 |
|
|
| 1,464 |
|
|
| 1,386 |
|
Income before income tax expense |
| 87,704 |
|
|
| 57,947 |
|
|
| 78,831 |
|
Income tax expense |
| 20,371 |
|
|
| 4,412 |
|
|
| 8,983 |
|
Net income | $ | 67,333 |
|
| $ | 53,535 |
|
| $ | 69,848 |
|
Percentage of revenue |
| 24 | % |
|
| 22 | % |
|
| 29 | % |
|
|
|
|
|
| ||||||
Net income per weighted-average common and common-equivalent share: |
|
|
|
|
| ||||||
Basic | $ | 0.39 |
|
| $ | 0.30 |
|
| $ | 0.40 |
|
Diluted | $ | 0.38 |
|
| $ | 0.30 |
|
| $ | 0.39 |
|
|
|
|
|
|
| ||||||
Weighted-average common and common-equivalent shares outstanding: |
|
|
|
|
| ||||||
Basic |
| 174,146 |
|
|
| 176,123 |
|
|
| 176,288 |
|
Diluted |
| 176,668 |
|
|
| 179,322 |
|
|
| 179,971 |
|
|
|
|
|
|
| ||||||
Cash dividends per common share | $ | 0.065 |
|
| $ | 0.065 |
|
| $ | 0.060 |
|
Cash and investments per common share | $ | 4.57 |
|
| $ | 5.17 |
|
| $ | 4.96 |
|
Book value per common share | $ | 7.82 |
|
| $ | 8.15 |
|
| $ | 7.68 |
|
|
|
|
|
|
| ||||||
(1) Amounts include stock-based compensation expense, as follows: |
|
|
|
|
| ||||||
Cost of revenue | $ | 563 |
|
| $ | 380 |
|
| $ | 248 |
|
Research, development, and engineering |
| 4,448 |
|
|
| 3,377 |
|
|
| 4,003 |
|
Selling, general, and administrative |
| 10,045 |
|
|
| 6,664 |
|
|
| 7,758 |
|
Total stock-based compensation expense | $ | 15,056 |
|
| $ | 10,421 |
|
| $ | 12,009 |
|
|
|
|
|
|
|
Exhibit 2 | |||||||||||
COGNEX CORPORATION | |||||||||||
Reconciliation of Selected Items from GAAP to Non-GAAP | |||||||||||
(Unaudited) | |||||||||||
Dollars in thousands, except per share amounts | |||||||||||
| |||||||||||
| Three-months Ended | ||||||||||
| Apr. 3, 2022 |
| Dec. 31, 2021 |
| Apr. 4, 2021 | ||||||
Discrete tax adjustments reconciliation |
|
| |||||||||
Income before income tax expense (GAAP) | $ | 87,704 |
|
| $ | 57,947 |
|
| $ | 78,831 |
|
|
|
|
|
|
| ||||||
Income tax expense (GAAP) | $ | 20,371 |
|
| $ | 4,412 |
|
| $ | 8,983 |
|
Effective tax rate (GAAP) |
| 23 | % |
|
| 8 | % |
|
| 11 | % |
|
|
|
|
|
| ||||||
Discrete tax benefit (expense) related to stock-based compensation |
| (117 | ) |
|
| 1,148 |
|
|
| 5,207 |
|
Discrete tax benefit (expense) related to tax return filings and other |
| (6,221 | ) |
|
| (1,173 | ) |
|
| — |
|
Total discrete tax adjustments | $ | (6,338 | ) |
| $ | (25 | ) |
| $ | 5,207 |
|
|
|
|
|
|
| ||||||
Income tax expense (Non-GAAP) | $ | 14,033 |
|
| $ | 4,387 |
|
| $ | 14,190 |
|
Effective tax rate (Non-GAAP) |
| 16 | % |
|
| 8 | % |
|
| 18 | % |
|
|
|
|
|
| ||||||
Net income (Non-GAAP) | $ | 73,671 |
|
| $ | 53,560 |
|
| $ | 64,641 |
|
Percentage of revenue (Non-GAAP) |
| 26 | % |
|
| 22 | % |
|
| 27 | % |
|
|
|
|
|
| ||||||
Net income per diluted weighted-average common and common-equivalent share (GAAP) | $ | 0.38 |
|
| $ | 0.30 |
|
| $ | 0.39 |
|
Per share impact of discrete tax adjustments identified above |
| 0.04 |
|
|
| — |
|
|
| (0.03 | ) |
Net income per diluted weighted-average common and common-equivalent share (Non-GAAP) | $ | 0.42 |
|
| $ | 0.30 |
|
| $ | 0.36 |
|
|
|
|
|
|
| ||||||
Diluted weighted-average common and common-equivalent shares outstanding (GAAP) |
| 176,668 |
|
|
| 179,322 |
|
|
| 179,971 |
|
|
|
|
|
|
|
Exhibit 3 | |||||
COGNEX CORPORATION | |||||
Balance Sheets | |||||
(Unaudited) | |||||
Dollars in thousands | |||||
| Apr. 3, 2022 |
| Dec. 31, 2021 | ||
Assets |
|
|
| ||
Cash and investments | $ | 794,164 |
| $ | 907,364 |
Accounts receivable |
| 155,065 |
|
| 130,348 |
Inventories |
| 136,660 |
|
| 113,102 |
Property, plant, and equipment |
| 77,870 |
|
| 77,546 |
Operating lease assets |
| 32,217 |
|
| 23,157 |
Goodwill and intangible assets |
| 252,228 |
|
| 253,601 |
Deferred tax assets |
| 412,333 |
|
| 418,570 |
Other assets |
| 73,578 |
|
| 79,974 |
|
|
|
| ||
Total assets | $ | 1,934,115 |
| $ | 2,003,662 |
|
|
|
| ||
Liabilities and Shareholders' Equity |
|
|
| ||
Accounts payable and accrued expenses | $ | 107,855 |
| $ | 136,483 |
Deferred revenue and customer deposits |
| 54,455 |
|
| 35,743 |
Operating lease liabilities |
| 34,530 |
|
| 25,581 |
Income taxes |
| 83,585 |
|
| 66,517 |
Deferred tax liabilities |
| 279,729 |
|
| 293,769 |
Other liabilities |
| 15,216 |
|
| 15,476 |
Shareholders' equity |
| 1,358,745 |
|
| 1,430,093 |
|
|
|
| ||
Total liabilities and shareholders' equity | $ | 1,934,115 |
| $ | 2,003,662 |
Last Trade: | US$39.95 |
Daily Change: | -0.03 -0.08 |
Daily Volume: | 432,025 |
Market Cap: | US$6.850B |
October 30, 2024 July 31, 2024 May 02, 2024 |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MOREElse Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS